ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities rises 131.6% from a year ago

Other current liabilities stood at $150.52M at the end of Q1 FY2026, up 131.6% from a year earlier and down 24.1% from the prior quarter. Over 3 fiscal years it compounded at +65.5% a year.

Context

  • Other current liabilities amounted to 10.6% of total assets at the end of Q1 FY2026, up 5.6 pp from a year earlier.
  • Other current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +131.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$150.52M-24.1% QoQ
Last fiscal yearDec 2025
$198.26M+157.4% YoY
Year agoMar 2025
$64.99M+131.6% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+131.6%——
1 year+157.4%——
3-year CAGR+65.5%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
198.26M USD
Year-over-year change
+157.4%
4-year CAGR
+45.5%

Other Current Liabilities vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +131.6% is the 3rd highest of 7, against a peer median of -7.0%.
  • Other current liabilities amounts to 10.6% of total assets for ANIP, versus a peer median of 5.8%.
ANIP Competitors
Other Current Liabilities for ANIP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹55.25B INR+260.9%+90.4%9.6%
TEVATeva Pharmaceutical Industries LimitedJun 2026$5.69B USD-2.0%+16.3%14.3%
BHCBausch Health Companies Inc.Jun 2026$1.2B USD-12.0%+28.7%4.8%
VTRSViatris Inc.Jun 2026$865.7M USD-34.4%+32.5%2.5%
COLLCollegium Pharmaceutical, Inc.Mar 2026$393.4M USD+1196.2%+531.1%23.8%
ANIPANI Pharmaceuticals, Inc.Mar 2026$150.52M USD+131.6%+65.5%10.6%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$88.17M USD-16.0%+25.9%2.3%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$86.62M USD——5.3%
HROWHarrow Health, Inc.Mar 2026$52.6M USD——12.5%
EOLSEvolus, Inc.Mar 2026$14.07M USD——6.4%
LFCRLifecore Biomedical, Inc.Dec 2025$6.05M USD——2.6%
Peer median (excluding ANIP) —-7.0%+30.6%5.8%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents100.3M48.23M221.12M144.86M285.59M
Short-term Investments0006.31M0
Net Receivables128.53M165.44M162.08M221.73M281.08M
Inventory81.69M105.36M111.2M136.78M143.07M
Other Current Assets3.67M21.41M25.42M18.01M43.38M
Total Current Assets321.78M344.26M519.82M527.68M753.12M
Property, Plant & Equipment (Net)52.67M43.25M44.59M56.86M62.48M
Goodwill27.89M28.22M28.22M59.99M62.48M
Intangible Assets294.12M251.64M209.01M541.83M479.53M
Long-term Investments5M06.2M00
Tax Assets67.94M81.36M90.71M85.11M69.07M
Other Non-current Assets2.21M11.36M5.87M12.22M13.71M
Total Non-current Assets449.82M415.83M384.61M756.01M687.26M
Total Assets771.6M760.09M904.42M1.28B1.44B
Account Payables22.97M29.31M36.68M45.66M62.58M
Short-term Debt850K850K850K9.17M17.27M
Tax Payables3.67M08.16M6.75M11.03M
Deferred Revenue87K0000
Other Current Liabilities44.27M43.71M65.73M77.03M198.26M
Total Current Liabilities87.54M99.44M145.48M193.68M278.11M
Long-term Debt286.52M285.67M284.82M614.92M307.93M
Deferred Tax Liabilities9.49M0000
Deferred Revenue (Non-current)(9.49M)0000
Other Non-current Liabilities38.8M36.44M16.53M46.57M313.61M
Total Non-current Liabilities325.32M322.11M301.35M661.49M621.54M
Total Liabilities412.86M421.55M446.82M855.17M899.65M
Common Stock1K1K2K2K3K
Retained Earnings(47.77M)(97.29M)(80.13M)(100.28M)(23.1M)
Accumulated OCI(3.06M)12.17M8.86M5.34M1.03M
Other Stockholders Equity00000
Minority Interest00000
Total Equity358.74M338.54M457.6M428.53M540.72M
Total Debt287.37M286.52M285.67M624.09M325.2M
Net Debt187.07M238.29M64.55M479.23M39.61M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.